skip to Main Content

Parkinson’s Foundation: PD Generation: Mapping the Future of Parkinson’s Disease


Brief Summary:

To assess the feasibility, impact, and participant satisfaction of offering Clinical
Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care
for People with Parkinson’s disease (PWP).


Inclusion Criteria:

1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson’s
Disease: probable diagnosis.

2. Willingness to undergo genetic testing, and choose to be informed of genetic testing
results for Glucosylceramidase Beta (GBA), LRRK2 and 5 additional PD related genes

3. Capacity to give full informed consent in writing, and have read and signed the
informed consent forms (ICFs) based on clinician’s determination.

4. Able to perform study activities (including completion of either online, in-person or
paper surveys).

5. Individuals must speak and understand the English language.

Exclusion Criteria:

1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy,
progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome),
including that due to medications, metabolic disorders, encephalitis, cerebrovascular
disease, or normal pressure hydrocephalus.

2. Individuals who have received a blood transfusion within the past 3 months.

3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.

4. Individuals who have had a bone marrow transplant within the past 5 years.


  • University of California San Diego (UCSD), La Jolla, California, United States, 92093
Back To Top